First-In-Human Evaluation of [18F]Fluproxadine for Norepinephrine Transporter PET
Authors:
- Tomohiko YamaneTYTomohiko Yamane
- Hitoshi IimoriHIHitoshi Iimori
- Go AkamatsuGAGo Akamatsu
- Yasuhiko IkariYIYasuhiko Ikari
- Yuki HodaYHYuki Hoda
- Keiji ShimizuKSKeiji Shimizu
- Keiichi MatsumotoKMKeiichi Matsumoto
- Michio SendaMSMichio Senda
- Rudolf A. WernerRWRudolf A. Werner
- Naoko NoseNNNaoko Nose
- Xinyu ChenXCXinyu Chen
- Takahiro HiguchiTHTakahiro Higuchi
Open Access
- 27 April 2026
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (7) , 555-564
Abstract
Background: Current norepinephrine transporter (NET) tracers used for cardiac sympathetic imaging and oncology are limited by radiosynthesis complexity, suboptimal image quality, or operational constraints. [ 18 F]fluproxadine (formerly [ 18 F]AF78) was developed to address these limitations by providing high NET affinity, favorable biodistribution, and an operationally straightforward radiosynthesis. We therefore conducted the first-in-human evaluation of this new class of [ 18 F] labeled NET PET tracer to assess its safety, biodistribution, radiation dosimetry, and imaging characteristics. Patients and Methods: In a prospective study, 4 healthy adult volunteers received [ 18 F]fluproxadine (101.8–204.0 MBq). Dynamic whole-body PET/CT acquisitions were obtained 10 times from 1 to 232 minutes postinjection, and vital signs, laboratory tests, and adverse events were monitored. Time-activity curves were generated for major organs, including myocardium from the whole-body scans, and organ-absorbed doses and effective dose were estimated using OLINDA/EXM v2.0 from time-integrated activities. Myocardial uptake and target-to-background behavior were assessed using semiquantitative methods. Radiosynthesis performance and key operational steps were documented to assess practical scalability. Results: Radiosynthesis of [ 18 F]fluproxadine was operationally straightforward with encouraging yields and fewer specialized steps than some legacy tracers. Imaging was completed without serious adverse events. Biodistribution showed predominant renal clearance; biliary excretion was not observed within the imaging window. Highest organ doses were to the urinary bladder wall and kidneys, with additional uptake in liver, thyroid, salivary glands, and myocardium. The effective dose was 21.6±1.5 µSv/MBq. Myocardial uptake was clearly visualized on whole-body images with favorable target-to-background characteristics at delayed time points, consistent with NET biology and supporting practical cardiac imaging windows. Conclusions: [ 18 F]fluproxadine demonstrated clear myocardial uptake, acceptable radiation dosimetry comparable to typical 18 F PET agents, and an early safety profile without serious adverse events.Keywords
This publication has 27 references indexed in Scilit:
- Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical OutcomesCurrent Cardiology Reports, 2025
- Incident heart failure and recurrent coronary events following acute myocardial infarctionEuropean Heart Journal, 2025
- OLINDA/EXM 2—The Next-generation Personal Computer Software for Internal Dose Assessment in Nuclear MedicineHealth Physics, 2023
- 123I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Initial Evaluation of AF78: a Rationally Designed Fluorine-18-Labelled PET Radiotracer Targeting Norepinephrine TransporterMolecular Imaging and Biology, 2020
- Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvementsJournal of Neural Transmission, 2020
- Reliable quantification of myocardial sympathetic innervation and regional denervation using [11C]meta-hydroxyephedrine PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paragangliomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear CardiologyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Comparison of [123I]metaiodobenzylguanidine kinetics with heart rate variability and plasma norepinephrine levelJournal of Nuclear Cardiology, 1997